Ubrogepant

Indications

Ubrogepant is used for: Migraine

Adult Dose

Migraine Indicated for acute treatment of migraine with or without aura 50-100 mg PO for acute migraine If needed, may take second dose at least 2 hr after initial dose Maximum dose: 200 mg/24 hr Safety of treating >8 migraines/30-day period not established Hepatic impairment Mild or moderate (Child-Pugh A or B): No dose adjustment required Severe (Child-Pugh C) Initial dose: 50 mg Second dose (if needed): 50 mg

Child Dose

Renal Dose

Renal impairment Mild or moderate (CrCl ?30 mL/min): No dose adjustment required Severe (CrCl 15-29 mL/min) Initial dose: 50 mg Second dose (if needed): 50 mg End-stage renal disease (CrCl <15 mL/min) Avoid

Administration

Contra Indications

Coadministration with strong CYP3A4 inhibitors

Precautions

Pregnancy-Lactation

Pregnancy Data are not available regarding risk associated with use in pregnant women Animal studies Administration in rats during organogenesis resulted in no adverse effects on embryofetal development Rabbits Administration produced abortion and increased embryofetal mortality in surviving litters at high dose (250 mg/kg/day) In a second study, excessive maternal toxicity at the high dose (250 mg/kg/day) resulted in early termination and lack of fetal data for that dose group Clinical considerations Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy Lactation Data are not available regarding presence in human milk, effect on breastfed infants, or effects on milk production

Interactions

Adverse Effects

Side effects of Ubrogepant : 1-10% 50 mg Nausea (2%) Somnolence (2%) 100 mg Nausea (4%) Somnolence (3%) Dry mouth (2%) <1% 50 mg Dry mouth

Mechanism of Action

Highly potent, orally administered calcitonin gene-related peptide (CGRP) receptor antagonist; binds to CGRP receptor, which is thought to be causally involved in migraine pathophysiology